Biocon’s shares surged by 8% on Tuesday due to strong Q4 earnings growth. Net profit grew by 31% to INR 313 crore with 57% YoY growth in consolidated revenue from operations totaling INR 3,774 crore. Operating profit EBITDA surged 75% while gross spending on R&D rose by 53% to INR 356 crore. The biosimilars business stood out with revenue more than doubling on YoY basis to INR 2,102 crore. However, despite strong results, Biocon reportedly missed estimates, according to Motilal Oswal.
Union Bank of India approves plan to raise up to Rs 20,000 crore via long-term bonds
Union Bank of India will raise funds through bond issuances. The bank’s committee approved long-term bonds worth twenty thousand crore rupees for infrastructure and affordable
March 16, 2026